APIC invests in Neuland facilities in Hyderabad to enable firm to produce APIs for Japanese market
Indian drug manufacturer Neuland Laboratories is expanding its presence in the Japanese market as a result of a new collaboration with Mitsubishi Healthcare unit API Corp (APIC) in Tokyo, Japan. APIC is investing in Neuland‘s facilities in Hyderabad to provide dedicated capacity that will enable Neuland to produce pharmaceutical ingredients and related products for APIC’s customers in Japan. No financial details have been released.
Neuland will operate the facility and the two companies will share oversight and management responsibilities.
‘We are impressed with Neuland’s long history of quality production and regulatory excellence. In addition, their business model of being solely focused on API and intermediates manufacture makes them an ideal partner for APIC,’ said Taiichi Emura, President of APIC.
Dr D R Rao, Chairman and Managing Director of Neuland Labs, said: ‘This alliance will allow us to raise our profile in Japan while enabling our partner APIC to grow their business in a cost-effective way.’
Neuland also intends independently to continue to expand its already-sizeable business in Japan, building on its significant customer base for both generic API manufacturing and contract manufacturing of APIs and intermediates.
Dr Rao added: ‘Our work with APIC has already been valuable in increasing our understanding of the unique requirements of the Japanese market. We are confident that we have adequate production capacity to serve both existing and new customers and believe that this collaboration will further enhance our ability to serve all of our customers around the globe.’
For more than 25 years Neuland Labs has been manufacturing APIs at its cGMP manufacturing facilities, working with customers in 85 countries. The company has developed more than 300 processes and 60 APIs, and has filed more than 40 US drug master files (DMFs), 10 EU CEPs and a total of more than 400 DMFs worldwide. Its manufacturing facilities are approved by the US FDA and other leading regulatory agencies.